CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 197 enrolled
Drug / intervention
Sputum and blood samplingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03151395
NCT03151395N/ACompleted

Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease (COPD) and During Acute Exacerbations of COPD (AECOPD), in Asia Pacific

GlaxoSmithKline·interventional·Posted May 12, 2017·Updated Jun 14, 2021

In Brief

A clinical study evaluating Sputum and blood sampling for Respiratory Disorders. Completed, enrolled 197 participants across 19 sites in 4 countries.

Detailed Summary

Since the infectious aetiology of AECOPD has been suggested to vary according to geographical region, the primary purpose of this study (which will be conducted in several countries in Asia Pacific) is to evaluate the occurrence of bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD. Given the increasing and projected burden of COPD in the Asia Pacific region, this study will also evaluate the frequency, severity and duration of AECOPD, as well as the impact of AECOPD on health-related quality of life (HRQOL), healthcare utilisation and lung function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesHong Kong, Philippines, South Korea, Taiwan
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 12, 2017
Enrollment StartAug 25, 2017
Primary CompletionApr 6, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.1 years ago

Interventions

Sputum and blood samplingother

Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.